7th April 2020: Orthobiologics, also termed as regenerative cellular treatments, are components that orthopedic specialists use to recover injuries more rapidly. Orthobiologics are used to recover the healing of injured muscles, broken bones, ligaments, and tendons. These products are made from constituents that are naturally found in your body.
Orthobiologics associated products comprise development factors that frequently secrete growth factors to recover pain, help rebuild the normal functioning, and facilitate tissue healing. These orthobiologics also have application for the treatment of situations such as spinal fusion and fracture recovery There are several categories of orthobiologics present in the industry, which depend on the various mechanism of actions.
Viscosupplementation Product Segment to Dominate in the Forecast Period
On the basis of product, the orthobiologics market can be classified into viscosupplementation, bone morphogenetic protein (BMP), demineralized bone matrix (DBM), stem cell therapy, synthetic bone substitutes, and allograft. High demand for viscosupplementation will lead to high adoption rate thereby boosting the segment.
The dominant share of the orthobiologics is attributed to high acceptance of these products because of widespread availability and unprecedented approval in diseases such as hip degenerative joint disease and osteoarthritis. In addition, the large share of product segment is attributed to lower cost of viscosupplementations and increasing occurrence of osteoarthritis of the hip and knee joints among the geriatric populace.
The high acceptance rate is supposed to be a significant advantage related to viscosupplementation. These advantages comprise reduced pain, better knee movement, fewer side effects, and relatively lesser invasive in nature. It is also supposed to be an outcome of extensive demand for minimally invasive operational procedures leading to high adoption by the patient populace base.
Spinal Fusion Accounted for Majority Share in the Application Segment.
The major application variants of the orthobiologics include reconstructive surgery, trauma repair, and spinal fusion. The spinal fusion sector accounted for more than half of the market share and is anticipated to expand at the fastest CAGR in the forthcoming period.
The growth of spinal infusion is attributed to demineralized bone matrices, constant saturation of bone morphogenetic proteins, and allografts and autografts in spinal fusion surgeries on account of its ability to offer rapid bone healing and high bone stability thereby improving long-term spinal diseases. Reduced hospital visits and stay duration and the fast stimulus of cells to start bone formation are the other benefits of orthobiological products in spinal fusion.
Hospitals Segment to have a Dominant Share in the End User Segment
On the basis of the end user, the orthobiologics can be classified into orthopedic clinics and hospitals. The hospital's sector accounted for the dominant share in the end user segment and is anticipated to expand at the fastest CAGR in the forthcoming period.
Increasing acceptance of orthobiological products in reconstructive and spinal surgeries performed in hospitals is a major factor attributed to the growth of the segment in the forecast period. Furthermore, the easy availability of a wide range of orthobiologics in hospitals and specialized patient care is likely to boost the demand for the market in the forecast period.
Additionally, frequent re-admissions, large procedure volumes, and high patient turnaround are contributing to the segment growth. Also, the supportive infrastructure facilities exact operative methods is further estimated to raise the growth potential of the segment in the years to come.
Market Insights:
The key companies include new product growth activities, distribution improvement strategies, and collaborations, frequent product approval and mergers & acquisitions. In May 2016, NuVasive Inc. introduced AttraX Putty, the next generation biologics technology, which is an artificial bone graft, designated in posterolateral spinal surgery, as an autograft extender. This introduction of the product was carried out to gain an advantage and increase the product range over the market players.
Medtronic is one of the topmost global players in the orthobiologics market on account of the rapid successful launch and fast acceptance for Infuse bone morphogenetic protein. This company is anticipated to withstand the highest share in the years to come on account of the robust sales force for Infuse and higher cost and FDA support received for the use of Infuse in new spine surgery indication in April 2018.
Leading players operating in the orthobiologics market include Smith & Nephew plc; Medtronic; Stryker Corporation; Genzyme; and DePuy Synthes, Inc.
No comments:
Post a Comment